Globus Medical, the Audubon, Pennsylvania-based medical device company, announced on August 26, 2026 that it has acquired Higgs Boson Health, a digital healthcare platform company incubated out of Duke University and headquartered in Durham, North Carolina. Neither company disclosed the purchase price or deal terms. David Paul, Globus Medical’s Founder and Executive Chairman, tied the acquisition to the company’s broader ambitions for surgical outcomes: “Higgs Boson employs highly experienced teams of software developers and AI scientists who will be joining our team to power our vision of a seamless digital healthcare environment to simplify a patient’s journey through our healthcare system while enhancing real-time information and surgical intelligence available to healthcare providers with the ultimate goal of getting to 95% good outcomes at 10 years for all musculoskeletal surgeries.” President and CEO Keith Pfeil framed the deal as filling a specific gap in Globus’s product lineup: “The acquisition of Higgs Boson and its digital solutions represents the next step in our strategy of enhancing the Globus ecosystem. As we continue to build out the ecosystem, the Higgs Boson technology will be part of our surgical intelligence pillar, bringing together outcomes and analytics in a closed-loop manner that fosters continuous learning, integrating along the full patient journey with the goal of improving patient outcomes.”
What Higgs Boson Actually Built
Higgs Boson Health was founded in 2017 by CEO Rajeev Dharmapurikar along with Dr. Nandan Lad, a Duke professor of neurosurgery, and Dr. Ziad Gellad, a Duke professor of medicine. Its flagship product, now called CareConvoy after a 2023 rebrand from its original name, Manage My Surgery, is a patient engagement platform that guides people through the pre- and post-operative surgical journey while giving care teams real-time visibility into how patients are doing between office visits. Dharmapurikar described the founding premise in the companies’ joint announcement: “We built Higgs Boson Health on the belief that what happens before and after surgery matters as much as what happens in the operating room. Joining Globus Medical lets us close that loop at a scale we could not reach alone, turning every recovery into insight that makes the next surgery better.” Co-founder Lad added that folding the platform into Globus gives it much broader reach: “As a neurosurgeon, I see every day how much of a patient’s outcome is decided outside the operating room. With Globus Medical, we can put that intelligence in the hands of surgical teams across the entire medical, interventional and surgical care pathway.” Gellad framed the value in terms of what patient-reported data can catch: “From the beginning, our goal was to elevate the patient’s voice in their surgical care. Every record a patient shares is a chance to catch a problem earlier and guide a recovery better. Globus Medical shares that commitment to measuring what matters and acting on it.”
More of an Acqui-Hire Than a Revenue Play
Higgs Boson arrives at Globus as a small company by financial measures. Independent analysis of the deal found Higgs Boson had raised only about $820,000 across two funding rounds since its 2017 founding, and characterized the acquisition as effectively an “acqui-hire” bringing in Higgs Boson’s software developers and AI scientists rather than a meaningful standalone revenue business. That analysis argued the real value of a patient-engagement platform like CareConvoy for a spine and orthopedic implant maker isn’t software sales at all, but stickiness: a hospital using Globus’s outcomes-tracking and surgical-planning tools around a procedure becomes a harder relationship to walk away from when it comes time to choose implant vendors again. The deal slots into what Globus describes as a four-pillar ecosystem strategy spanning implants and instruments, enabling technology like its ExcelsiusGPS robotic surgery platform, procedural solutions for spine surgery, and now a “surgical intelligence” pillar that had been largely unfilled before this acquisition.
A Modest Deal for a Company Guiding Toward $3.2 Billion
Financially, this acquisition is a rounding error next to Globus Medical’s overall business. The company closed 2025 with $2.94 billion in total net sales (its base business, excluding the Nevro acquisition, accounted for $2.65 billion of that) and has reaffirmed 2026 guidance of $3.18 billion to $3.22 billion, meaning Higgs Boson’s technology and team, whatever the undisclosed purchase price, represents a capability addition rather than a scale-driven move for a company already operating at that size.
About Globus Medical, Inc.
Globus Medical, Inc. is a leading global musculoskeletal technology company dedicated to solving unmet clinical needs and changing lives. We innovate with inspired urgency, provide world-class education and clinical support, and advance care throughout spine, orthopedic trauma, joint reconstruction, biomaterials and enabling technologies. Additional information can be accessed at www.globusmedical.com.
